Cost analysis in a Medicaid program for patients with bipolar disorder who initiated atypical antipsychotic monotherapy^*

References

• Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of twelve-month DSM-IV disorders in the National Comorbidity Survey Replication (NCS-R). Arch Gen Psychiatr 2005;62:617-27
   PubMed Web of Science ®Google Scholar
• Begley CE, Annegers JF, Swann AC, et al. The lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998. Pharmacoeconomics 2001;19(5 pt 1):483-95
   Web of Science ®Google Scholar
• Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry 1999;156:702-9
   PubMed Web of Science ®Google Scholar
• Tohen M, Baker RW, Alsulter LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159:1011-17
   PubMed Web of Science ®Google Scholar
• Keck PE Jr. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry 2005;66 (Suppl. 3):5-11
   PubMed Web of Science ®Google Scholar
• Duggan M. Do new prescription drugs pay for themselves? The case of second-generation antipsychotics. J Health Economics 2005;24:1-31
   PubMed Web of Science ®Google Scholar
• Gianfrancesco FD, Pesa J, Wang RH, et al. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. J Managed Care Pharmacy 2005;11:220-30
   PubMedGoogle Scholar
• Bridle C, Plamer S, Bagnall AM, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Tech Assess 2004;8:1-187
   Web of Science ®Google Scholar
• Frankle WG, Perlis RH, Deckersbach T, et al. Bipolar depression: relationship between episode length and antidepressant treatment. Psychol Med 2002;32:1417-23
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei A, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• D’Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of charlson comorbidity index with administrative databases. J Clin Epidemiol 1996;49:1429-33
   PubMed Web of Science ®Google Scholar
• Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999;156:1417-20
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997;50:105-16
   PubMed Web of Science ®Google Scholar
• Heckman JJ. Sample selection bias as a specification error. Econometrica 1979;47:153-62
   Web of Science ®Google Scholar
• Dubin AJ, McFadden LD. An econometric analysis of residential electric appliance holdings and consumption. Econometrica 1984;52:345-62
   Web of Science ®Google Scholar
• Stillman S. Inverse Mills Ratio after MLOGIT. Available at:http://www.stata.com/statalist/archive/2003-04/msg00465.html [Last accessed 11 November 2008]
   Google Scholar
• Blough, DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ 1999;18:153-71
   PubMed Web of Science ®Google Scholar
• Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-95
   PubMed Web of Science ®Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94
   PubMed Web of Science ®Google Scholar
• Bouckaet A, Crott R. The difference in mean costs as a pharmacoeconomic outcome variable: power considerations. Control Clin Trials 1997;18:58-64
   PubMedGoogle Scholar
• Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health 1999;20:125-44
   PubMed Web of Science ®Google Scholar
• Gilmore TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9
   PubMed Web of Science ®Google Scholar
• Zhao Z. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia. Managed Care Interface 2002;15:75-81
   PubMedGoogle Scholar
• Rascati KL, Johnsrud MT, Crismon ML, et al. Olanzapine versus risperidone in the treatment of schizophrenia. Pharmacoeconomics 2003;21:683-97
   PubMed Web of Science ®Google Scholar
• Fuller MA, Shermock KM, Secic M, et al. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Serv 2002;53:855-60
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159 (Suppl. 4):1-50
   Web of Science ®Google Scholar
• Fu AZ, Christensen DB, Hansen RA, et al. Second-generation antidepressant discontinuation and depressive relapse in adult patients with bipolar depression: results of a retrospective database analysis. Clin Therapeut 2006;28:979-89
   PubMed Web of Science ®Google Scholar
• Fu AZ, Dow WH, Liu GG. Propensity score and difference-in-difference methods: a study of second-generation antidepressant use in patients with bipolar disorder. Health Serv Outcome Res Meth 2007;7:23-38
   Google Scholar
• Fu AZ, Liu GG, Christensen DB, et al. Effect of second-generation antidepressants on mania- and depression-related visits in adults with bipolar disorder: a retrospective study. Value Health 2007;10:128-36
   PubMed Web of Science ®Google Scholar
• Kamat SA, Rajagopalan K, Pethick N, et al. Prevalence and humanistic impact of potential misdiagnosis of bipolar disorder among patients with major depressive disorder in a commercially insured population. J Manag Care Pharm 2008;14:632-42
   Web of Science ®Google Scholar
• D’Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
   PubMed Web of Science ®Google Scholar